A BILL 
To require the Comptroller General of the United States 
to study the role pharmacy benefit managers play in 
the pharmaceutical supply chain and to provide Congress 
with appropriate policy recommendations, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Pharmacy Benefit 
4
Manager Accountability Study Act of 2019’’. 
5
23:47 Jun 14, 2019
H3223
2 
•HR 3223 IH
SEC. 2. STUDY BY COMPTROLLER GENERAL OF UNITED 
1
STATES. 
2
(a) IN GENERAL.—The Comptroller General of the 
3
United States shall, in consultation with appropriate 
4
stakeholders, conduct a study on the role of pharmacy 
5
benefit managers with respect to federally facilitated Ex-
6
changes operated pursuant to section 1321(c) of the Pa-
7
tient Protection and Affordable Care Act (42 U.S.C. 
8
18041(c)). 
9
(b) PERMISSIBLE EXAMINATION.—In conducting the 
10
study required under subsection (a), the Comptroller Gen-
11
eral may examine various qualitative and quantitative as-
12
pects of the role of pharmacy benefit managers with re-
13
spect to federally facilitated Exchanges described in such 
14
subsection, such as the following: 
15
(1) The role that pharmacy benefit managers 
16
play in the pharmaceutical supply chain of such Ex-
17
changes. 
18
(2) The state of competition among pharmacy 
19
benefit managers on such Exchanges, including the 
20
market share for the Nation’s largest pharmacy ben-
21
efit managers. 
22
(3) The use of rebates and fees by pharmacy 
23
benefit managers with respect to such Exchanges, 
24
including— 
25
23:47 Jun 14, 2019
H3223
3 
•HR 3223 IH
(A) the extent to which rebates are passed 
1
on to qualified health plans offered on such Ex-
2
changes and whether such rebates are passed 
3
on to individuals enrolled in such plans; 
4
(B) the extent to which rebates are kept by 
5
such pharmacy benefit managers; and 
6
(C) the role of any fees charged by such 
7
pharmacy benefit managers. 
8
(4) Whether pharmacy benefit managers struc-
9
ture their formularies with respect to such Ex-
10
changes in favor of high-rebate prescription drugs 
11
over lower-cost, lower-rebate alternatives. 
12
(5) The average prior authorization approval 
13
time for pharmacy benefit managers with respect to 
14
such Exchanges. 
15
(6) Factors affecting the use of step therapy by 
16
pharmacy benefit managers with respect to such Ex-
17
changes. 
18
(7) The extent to which the price that phar-
19
macy benefit managers charge private payors on 
20
such Exchanges for a drug is more than such phar-
21
macy benefit managers pay the pharmacy for the 
22
drug. 
23
(c) REPORT.—Not later than the date that is three 
24
years after the date of enactment of this Act, the Comp-
25
23:47 Jun 14, 2019
H3223
4 
•HR 3223 IH
troller General shall submit to the Secretary of Health and 
1
Human Services, the Committee on Health, Education, 
2
Labor, and Pensions of the Senate, and the Committee 
3
on Energy and Commerce of the House of Representatives 
4
a report containing the results of the study conducted 
5
under subsection (a), including policy recommendations. 
6
Æ 
23:47 Jun 14, 2019
H3223
